Home
About Us
Company Overview
Mission
Leadship
Milestones
Science
Technology Platforms
Research Areas
Pipeline
Partnerships
News
News
Contact Us
EN
中文
EN
Home
About Us
Science
Technology Platforms
Research Areas
Pipeline
Partnerships
News
News
Contact Us
News
News
News
08-08
2022
Sciwind Biosciences Reports Positive Interim Results from Phase 1c/2a Clinical Trial of XW003 (Ecnoglutide) in Overweight and Obese Adult Volunteers in China
2022-08-08
08-02
2022
Sciwind Biosciences Announces Positive Topline Results from 20-week Phase 2 Clinical Trial of XW003 (Ecnoglutide), a novel long-lasting GLP-1 analogue, in Adult Patients with Type 2 Diabetes in China
2022-08-02
06-08
2022
Sciwind Biosciences to present Data from its GLP-1 and GIP Receptor Agonist Programs at The International Liver Congress(TM) EASL 2022
2022-06-08
04-13
2022
Sciwind Biosciences Announces Initiation of Dosing in Phase 1 Clinical Trial Evaluating XW004, an oral tablet formulation of its Proprietary GLP-1 Analogue (Ecnoglutide)
2022-04-13
01-17
2022
Sciwind Biosciences Announces Initiation of Patient Dosing in Phase 2b Clinical Trial Evaluating XW003, its Lead GLP-1 Drug Candidate, for the Treatment of Obesity
2022-01-17
12-09
2021
Sciwind Biosciences Completes Enrollment in Phase 2 Clinical Trial of XW003 in Type 2 Diabetes Patients
2021-12-09
<
1
2
3
4
5
>
